Iclusig comes too late to rescue Takeda
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
FDA critics barely lay a glove on Geron
Imetelstat appears headed for approval after its US adcom turns into a damp squib.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Novartis puts a €2.7bn BET on MorphoSys
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
Bayer and Lilly make radioligand progress
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
